BIO 2015 Dispatches: Can Expanding FDA's 'Breakthrough' Program Be An Answer To High Drug Costs?
This article was originally published in The Pink Sheet Daily
Executive Summary
America's Health Insurance Plans interim CEO Dan Durham says taking an indication-based approach, rather than the current product-specific approach, to awarding the designation would allow later-in-class products to reach market more quickly and help drive down the high cost of novel treatments approved under the expedited pathway.
You may also be interested in...
More Me-Too Drugs Please, FDA’s Jenkins Asks Industry
FDA’s top new drug official called out industry’s innovation model, noting that major primary care markets are being left underserved as sponsors focus on precision medicine and rare diseases.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.
RWE: Non-Interventional Studies Must Be Able To Distinguish A True Treatment Effect, US FDA Says
Agency describes a host of issues sponsors should consider and address before pursuing observational or case-control studies to support regulatory decision-making on drug efficacy or safety; new draft guidance was issued under the FDA’s Real-World Evidence program.